Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics. | |
Chi, Yihebali; Gao, Ming; Zhang, Yuan; Shi, Feng; Cheng, Ying; Guo, Zhuming; Ge, Minghua; Qin, Jianwu; Zhang, Jiewu; Li, Zhendong | |
刊名 | JOURNAL OF CLINICAL ONCOLOGY |
2021-05-20 | |
卷号 | 39 |
ISSN号 | 0732-183X |
DOI | 10.1200/JCO.2021.39.15_suppl.6022 |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | LIPPINCOTT WILLIAMS & WILKINS |
WOS记录号 | WOS:000708120603213 |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126616] |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.China Med Univ, Tumor Hosp, Liaoning Tumor Hosp & Inst, Shenyang, Peoples R China 2.Hunan Canc Hosp, Changsha, Peoples R China 3.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc,Tianjin Union Med Ctr, Tianjin, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China 5.Chinese Acad Sci, Zhejiang Prov Peoples Hosp, Peoples Hosp,Univ Chinese Acad Sci, Hangzhou Med Coll,ICBM,Canc Hosp,Zhejiang Canc Ho, Zhengzhou, Peoples R China 6.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China 7.Jilin Canc Hosp, Changchun, Peoples R China 8.Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Peoples R China 9.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China 10.Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China |
推荐引用方式 GB/T 7714 | Chi, Yihebali,Gao, Ming,Zhang, Yuan,et al. Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
APA | Chi, Yihebali.,Gao, Ming.,Zhang, Yuan.,Shi, Feng.,Cheng, Ying.,...&Tang, Pingzhang.(2021).Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics..JOURNAL OF CLINICAL ONCOLOGY,39. |
MLA | Chi, Yihebali,et al."Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论